Recently, clinical trials showed that nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, produced durable objective responses for treatment of HCC, indicating the possibility of combining nivolumab with AFP to suppress the proliferation of cancer cells [77]. This evidence concerns the gene AFP and hepatocellular carcinoma.